BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
BridgeBio Pharma (Nasdaq: BBIO) announced an upcoming investor webinar scheduled for July 11, 2025, at 8:00 am ET. The webinar will feature Dr. Matthew Wicklund, a distinguished Professor of Neurology from UT Health Science Center San Antonio, who will discuss limb-girdle muscular dystrophy (LGMD), with a focus on LGMD2I/R9.
The presentation will include insights from Dr. Wicklund, who has extensive experience with over 35 multi-center clinical trials and 200+ publications. Additionally, executive members will provide updates on the BBP-418 program and discuss anticipated Phase 3 interim analysis results expected in H2 2025. The webinar will be accessible through BridgeBio's investor website, with a replay available for 30 days.
BridgeBio Pharma (Nasdaq: BBIO) ha annunciato un webinar per investitori previsto per il 11 luglio 2025 alle 8:00 ET. Durante il webinar interverrà il Dr. Matthew Wicklund, stimato Professore di Neurologia presso l'UT Health Science Center di San Antonio, che parlerà della distrofia muscolare dei cingoli (LGMD), con particolare attenzione alla LGMD2I/R9.
La presentazione includerà approfondimenti del Dr. Wicklund, che vanta una vasta esperienza con oltre 35 studi clinici multicentrici e più di 200 pubblicazioni. Inoltre, i membri esecutivi forniranno aggiornamenti sul programma BBP-418 e discuteranno i risultati previsti dell’analisi intermedia di Fase 3 attesa nella seconda metà del 2025. Il webinar sarà accessibile tramite il sito web per investitori di BridgeBio, con la possibilità di rivederlo per 30 giorni.
BridgeBio Pharma (Nasdaq: BBIO) anunció un próximo seminario web para inversores programado para el 11 de julio de 2025 a las 8:00 am ET. El seminario contará con la participación del Dr. Matthew Wicklund, distinguido Profesor de Neurología del Centro de Ciencias de la Salud de UT en San Antonio, quien hablará sobre la distrofia muscular de cintura (LGMD), enfocándose en LGMD2I/R9.
La presentación incluirá perspectivas del Dr. Wicklund, quien tiene amplia experiencia con más de 35 ensayos clínicos multicéntricos y más de 200 publicaciones. Además, los ejecutivos ofrecerán actualizaciones sobre el programa BBP-418 y discutirán los resultados anticipados del análisis intermedio de la Fase 3 esperado para la segunda mitad de 2025. El seminario será accesible a través del sitio web para inversores de BridgeBio, con una repetición disponible durante 30 días.
BridgeBio Pharma (나스닥: BBIO)는 2025년 7월 11일 오전 8시 ET에 예정된 투자자 웨비나를 발표했습니다. 이번 웨비나에는 UT 헬스 사이언스 센터 샌안토니오의 저명한 신경학 교수인 매튜 윅런 박사가 참여하여 팔다리 근육 이영양증(LGMD), 특히 LGMD2I/R9에 대해 설명할 예정입니다.
발표에는 35건 이상의 다기관 임상시험과 200건 이상의 출판물을 보유한 윅런 박사의 통찰이 포함됩니다. 또한, 경영진이 BBP-418 프로그램에 대한 최신 정보와 2025년 하반기 예상되는 3상 중간 분석 결과에 대해 논의할 예정입니다. 웨비나는 BridgeBio 투자자 웹사이트를 통해 접속 가능하며, 30일간 다시보기 서비스도 제공됩니다.
BridgeBio Pharma (Nasdaq : BBIO) a annoncé un prochain webinaire destiné aux investisseurs, prévu pour le 11 juillet 2025 à 8h00 ET. Le webinaire mettra en vedette le Dr Matthew Wicklund, professeur éminent de neurologie à l'UT Health Science Center de San Antonio, qui abordera la dystrophie musculaire des ceintures (LGMD), en se concentrant sur la LGMD2I/R9.
La présentation comprendra les analyses du Dr Wicklund, qui possède une vaste expérience avec plus de 35 essais cliniques multicentriques et plus de 200 publications. De plus, les membres de la direction fourniront des mises à jour sur le programme BBP-418 et discuteront des résultats prévus de l’analyse intermédiaire de phase 3 attendue au second semestre 2025. Le webinaire sera accessible via le site web investisseurs de BridgeBio, avec une rediffusion disponible pendant 30 jours.
BridgeBio Pharma (Nasdaq: BBIO) kündigte ein bevorstehendes Investoren-Webinar an, das für den 11. Juli 2025 um 8:00 Uhr ET geplant ist. Das Webinar wird Dr. Matthew Wicklund, einen renommierten Professor für Neurologie am UT Health Science Center San Antonio, präsentieren, der über Gliedergürteldystrophie (LGMD) sprechen wird, mit Schwerpunkt auf LGMD2I/R9.
Die Präsentation umfasst Einblicke von Dr. Wicklund, der über umfangreiche Erfahrung mit mehr als 35 multizentrischen klinischen Studien und über 200 Veröffentlichungen verfügt. Zudem werden Führungskräfte Updates zum BBP-418-Programm geben und die erwarteten Zwischenergebnisse der Phase-3-Analyse, die für die zweite Hälfte 2025 erwartet werden, besprechen. Das Webinar ist über die Investorenseite von BridgeBio zugänglich, mit einer 30-tägigen Wiedergabemöglichkeit.
- None.
- None.
PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, July 11, 2025 at 8:00 am ET with Matthew Wicklund, M.D., FAAN, Professor of Neurology and Vice Chair for Research, Department of Neurology at the University of Texas (UT) Health Science Center San Antonio.
Dr. Wicklund will provide an overview of limb-girdle muscular dystrophy (LGMD), specifically focusing on the disease burden, standard of care and unmet needs for those with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) (FKRP-related). He serves as director for the UT Health San Antonio MDA Multidisciplinary Care Center and is a member of the Limb-girdle Muscular Dystrophy Clinical Research Network and the Neuromuscular Study Group. Dr. Wicklund has participated in over 35 multi-center clinical trials in the areas of muscular dystrophy, ALS, and myasthenia gravis and has over 200 published articles, chapters and abstracts.
In addition to Dr. Wicklund, executive members of the LGMD2I/R9 program will review the progress of BBP-418 to date and discuss expectations for the Phase 3 interim analysis results expected in the second half of 2025.
To access the live webcast of BridgeBio’s investor webinar, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, and YouTube.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, VP Strategic Finance
ir@bridgebio.com
FAQ
When is BridgeBio's (BBIO) investor webinar for LGMD2I/R9 scheduled?
Who is the key speaker at BridgeBio's LGMD2I/R9 investor webinar?
What will be discussed at BridgeBio's (BBIO) July 2025 investor webinar?
How can investors access BridgeBio's LGMD2I/R9 webinar?
When are BridgeBio's Phase 3 interim analysis results for BBP-418 expected?
